Shopping Cart
- Remove All
- Your shopping cart is currently empty
EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC). |
In vitro | EGFR-IN-139 exhibits an inhibition rate of 90-100% for wild-type EGFR and 65-75% for L858R/T790M EGFR at a concentration of 1μM over 2 hours [1]. Additionally, when applied over 72 hours at concentrations ranging from 0-100 μM, EGFR-IN-139 inhibits A549, H1975, and Vero cells with IC50 values of 28.23, 29.46, and 180.9 μM, respectively [1]. |
Molecular Weight | 476.951 |
Formula | C27H25ClN2O4 |
Cas No. | 1574321-31-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.